HoyleCohen’s Quest Diagnostics DGX Stock Holding History

HoyleCohen’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$3.73M	Sell	27,275 -1,961	-7%	-$269K	0.28%	78
2024 Q1	$3.89M	Buy	29,236 +594	+2%	+$77.1K	0.3%	80
2023 Q4	$3.95M	Sell	28,642 -978	-3%	-$129K	0.32%	79
2023 Q3	$3.61M	Sell	29,620 -475	-2%	-$63.3K	0.33%	78
2023 Q2	$4.23M	Sell	30,095 -1,700	-5%	-$234K	0.37%	73
2023 Q1	$4.5M	Sell	31,795 -80	-0.3%	-$11.4K	0.42%	70
2022 Q4	$4.99M	Sell	31,875 -475	-1%	-$68.3K	0.5%	63
2022 Q3	$3.97M	Sell	32,350 -665	-2%	-$87.6K	0.43%	66
2022 Q2	$4.39M	Buy	33,015 +511	+2%	+$69.6K	0.46%	64
2022 Q1	$4.45M	Buy	32,504 +190	+0.6%	+$26.5K	0.38%	72
2021 Q4	$5.59M	Sell	32,314 -220	-0.7%	-$33.5K	0.46%	57
2021 Q3	$4.73M	Sell	32,534 -249	-0.8%	-$36.4K	0.45%	64
2021 Q2	$4.33K	Sell	32,783 -65	-0.2%	-$8.51K	0.34%	72
2021 Q1	$4.22M	Buy	32,848 +16	+0%	+$1.97K	0.43%	70
2020 Q4	$3.91M	Buy	+32,832	New	+$4M	0.45%	67

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HoyleCohen's DGX Position: Q2 2024 in Review

HoyleCohen reduced its Quest Diagnostics (DGX) stake by 6.7% in Q2 2024, selling an estimated $269K and leaving 27,275 shares worth $3.73M. The position accounts for 0.28% of the portfolio, ranked #78.

HoyleCohen first reported a position in DGX in Q4 2020 and has held it in 15 quarters since. The position peaked at $5.59M in Q4 2021. 837 funds tracked by Wall St. Rank hold DGX as of Q2 2024.

HoyleCohen held 27,275 shares of Quest Diagnostics worth $3.73M as of Q2 2024.
HoyleCohen sold 1,961 Quest Diagnostics shares in Q2 2024, an estimated $269K.
Quest Diagnostics made up 0.28% of HoyleCohen's portfolio in Q2 2024, its #78 holding.
HoyleCohen first reported a position in Quest Diagnostics in Q4 2020 and has held it in 15 quarters since.
HoyleCohen's Quest Diagnostics position peaked at $5.59M in Q4 2021.
837 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.